Brainsway Ltd (BWAY)

BrainsWay Ltd. is a depositary receipt listed on NASDAQ that represents common stock of BrainsWay Ltd., a healthcare equipment and supplies company focused on noninvasive neurostimulation treatments. Through its Deep Transcranial Magnetic Stimulation platform, the company develops and sells therapies used in the treatment of a range of mental health and neurological conditions, including major depressive disorder, anxious depression, obsessive-compulsive disorder, smoking addiction, bipolar disorder, post-traumatic stress disorder, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson’s disease. Its customers include doctors, hospitals, and medical centers in psychiatry. BrainsWay was founded in 2003 and is headquartered in Jerusalem, Israel. The listed security is an ADR, rather than a direct common equity listing.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-BWAY
$10.22
-25.0% Downside
Overvalued
$19.27
41.4% Upside
Undervalued
Great
0.0%
November 18, 2026
57.2x
6.8x
8.9x
539.8 M
460.3 M
1.3%
60.0%
6.5
61.3%
Valuation • Fair Value

Brainsway Ltd (NASDAQ-BWAY) Fair Value by Valuation Model

Review the available estimates for Brainsway Ltd (NASDAQ-BWAY), including DCF Fair Value, Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$10.22

Estimated downside of 25.0% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$11.55

Discounted cash flow valuation reference.

Ben Graham Formula Value

$2.61

Classic Ben Graham valuation formula reference.

Comps Fair Value

$8.89

Comparable-company valuation reference.

Analyst Price Target

$19.27

Analysts imply upside of 41.4%.

How to read these valuation models

Use the 6 available valuation references for Brainsway Ltd (NASDAQ-BWAY) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Brainsway Ltd (NASDAQ-BWAY)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

60.695 M

Current operating scale indicator.

Revenue Forecast

68.88 M

Forward revenue estimate.

EBITDA

8.483 M

Current operating profitability reference.

EBITDA Forecast

13.575 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Brainsway Ltd (NASDAQ-BWAY) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Brainsway Ltd (NASDAQ-BWAY)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-0.99

Higher caution zone on this screen.

Altman Z-Score

6.5

Relatively strong balance-sheet zone.

FCF / Net Income

61.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Brainsway Ltd (NASDAQ-BWAY). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Brainsway Ltd (NASDAQ-BWAY)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 18, 2026

Days to Earnings

57

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Brainsway Ltd (NASDAQ-BWAY), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Brainsway Ltd (NASDAQ-BWAY) Stock Forecast & Technical Outlook

Review Brainsway Ltd (NASDAQ-BWAY) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Brainsway Ltd (NASDAQ-BWAY) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Buy

The 1-hour technical read for Brainsway Ltd (NASDAQ-BWAY) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Brainsway Ltd (NASDAQ-BWAY) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Brainsway Ltd (NASDAQ-BWAY) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Brainsway Ltd (NASDAQ-BWAY) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Brainsway Ltd (NASDAQ-BWAY)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Brainsway Ltd (NASDAQ-BWAY) has a Strong Buy consensus, with 3 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 0
Sell 0
FAQ Fast Investor Answers

Brainsway Ltd (NASDAQ-BWAY) Stock FAQ

Data-supported answers about Brainsway Ltd (NASDAQ-BWAY), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$10.22
Estimated downside 25.0%
Valuation Rating
Overvalued
Estimated downside of 25.0%
Analyst Target
$19.27
Implied upside 41.4%
Financial Health
Great
Current financial-health read

The current fair value estimate for Brainsway Ltd (NASDAQ-BWAY) is $10.22. This implies an estimated downside of 25.0% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 25.0% versus the current market price.

The available analyst price target for Brainsway Ltd (NASDAQ-BWAY) is $19.27. The analyst target implies estimated upside of 41.4%.

The current financial health read for Brainsway Ltd (NASDAQ-BWAY) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Brainsway Ltd (NASDAQ-BWAY) is November 18, 2026.

The latest available data indicates no current dividend yield for Brainsway Ltd (NASDAQ-BWAY).

The current P/E ratio listed for Brainsway Ltd (NASDAQ-BWAY) is 57.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Brainsway Ltd is 539.8 M.

The current enterprise value listed for Brainsway Ltd is 460.3 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Brainsway Ltd is NASDAQ-BWAY, and the stock is listed on NASDAQ.

Brainsway Ltd (NASDAQ-BWAY) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Brainsway Ltd is 1.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Brainsway Ltd is 60.0%. Free float helps investors understand how much of the share base is available for public trading.